Open

A Study of Atrasentan in IgA Nephropathy (ASSIST)

The ASSIST study will evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Extended hours (M-F, early morning or evening)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide), Virginia

What will be asked of you

You will take atrasentan or the placebo as a tablet by mouth while also taking an SGLT2i. At each visit, you will meet with a member of the study team and fill out questionnaires. At some visits you will be asked for blood and urine samples.

Incentives

In-person visits:
Up to 14

Phone or online visits:
Up to 6

Total length of participation:
16 months

Looking for Specific Volunteers

Able to participate:

IgA Nephropathy diagnosed by kidney biopsy

Not eligible if:

History of transplant
Use of immunosupressant medications in the last 3 months

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Secondary Visit Location

UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Amy Mottl
Medicine-Nephrology

Study Type

Clinical or Medical
Interventional

Study Topics

Kidneys and Liver

IRB Number

23-1061

ClinicalTrials.gov

NCT05834738

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.